Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395753 · ClinicalTrials.gov registry record · Phase 2
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Debiopharm International.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT06395753 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 66 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06395753, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Debiopharm International.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Conditions Studied
Interventions
- DRUG Debio 4228
Study Locations (20)
California
- Bakersfield Institute of Advanced Urology - Bakersfield
- Grimaldi Urology - Chula Vista
- Valley Urology - Fresno
- Urology Group of Southern California - Los Angeles
- Advanced Urology - Los Angeles
- Tower Urology, - Los Angeles
- Alarcon Urology Center - Montebello
- Urology Center of Southern California - Murrieta
- Pasadena Urological Medical Group - Pasadena
Arizona
- Urologic Surgeons of Arizona - Mesa
- East Valley Urology Center of Arizona - Queen Creek
Florida
- AP Medical Research - Miami
- Biogenix Molecular - Miami
New York
- Icahn School of Medicine at Mount Sinai - New York
- New York Cancer and Blood Specialists - Shirley
Indiana
- First Urology- Jeffersonville - Jeffersonville
Kansas
- GU Research Network/Wichita Urology Group - Wichita
North Carolina
- Associated Urologists of North Carolina - Raleigh
Oregon
- Oregon Urology Institut - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-05-23 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06395753
The ClinicalTrials.gov registry entry for NCT06395753 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Debio 4228 is the first listed.
NCT06395753 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06395753 about?
NCT06395753 is a clinical study titled "A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer". The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
What is the current status of trial NCT06395753?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-05-23. Estimated completion is 2027-01.
What conditions does trial NCT06395753 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06395753?
The interventions under investigation include: Debio 4228 (DRUG).
Who is sponsoring clinical trial NCT06395753?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06395753 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.